Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
- 206 Downloads
Purpose of this Review
This review summarizes the role of BCL-2 in the pathogenesis of CLL, and the clinical data evaluating safety and efficacy of venetoclax, in treatment of patients with CLL, in the context of other available targeted agents.
Venetoclax, alone or in combination with other targeted agents results in high rate of durable responses and undetectable measurable residual disease. Venetoclax maintains activity across all clinical and biologic subgroups, including those with high risk disease, including CLL with chromosome 17p deletion. TLS risk can be mitigated with risk stratification and five-week administration ramp-up schedule.
Venetoclax, a novel, orally bioavailable inhibitor of BCL-2 has demonstrated substantial clinical activity in the treatment of CLL. In combination with other targeted agents it can induce high disease response rates and potentially lead to MRD-negative durable remissions.
KeywordsCLL Venetoclax BCL-2
Bruton’s tyrosine kinase
Chronic lymphocytic leukemia
Progression free survival
Relapsed or refractory
Independent review committee
Minimal residual disease
Immunoglobulin heavy chain variable region
Tumor lysis syndrome
Compliance with Ethical Standards
Conflict of Interest
Herbert Eradat declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Bullrich F, Fujii H, Calin G, Mabuchi H, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Research. 2001;61(18):6640–8.Google Scholar
- 6.Institute, National Cancer. Surveillance epidemiology and end results cancer statistics review (SEER) database. 2016.Google Scholar
- 9.Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–54.Google Scholar
- 18.Migliazza, A, Bosch, F, Komatsu, H, Cayanis, E, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. 2001, Vol. 97, pp. 2098–2104.Google Scholar
- 19.Roberts, AW, Huang, DCS. Targeting BCL 2 with the BH3 mimetics: Basic science and clinical application of Venetoclax in chronic lymphocytic leukemia and related B cell malignancies. 2017, Vol. 101, pp. 89–98.Google Scholar
- 32.••Seymour JF, Ma S, Brander DM, Choi M, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. The Lancet oncology. 2017;18:230–40. Findings from this study established superior safety and efficacy of therapy with venetoclax and rituximab for patients with relapsed or refractory CLL, in comparison to cytotoxic chemoimmunotherapy with bendamustine and rituximab. For the first time, these MURANO data findings can lead to a paradigm shift in the treatment of patients with relapsed disease, utilizing a defined 2-year course of therapy that induces high response rates, with durable disease control. CrossRefGoogle Scholar
- 33.Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. British Journal of Hematology. 2015;170:669–78.CrossRefGoogle Scholar
- 36.•Jones JA, Mato AR, Wierda WG, Davids MS, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology. 2018;19(1):65–75. Findings in this study established the efficacy and safety of venetoclax after BTK inhibition, and provide clinical guidance on optimal sequencing of these agents. CrossRefGoogle Scholar
- 39.Anderson MA, Tam C, Lew T, Juneja S, Juneja M, Westerman D, et al. Clinical and pathological features and outcomes of progression of CLL on BCL-2 inhibitor venetoclax. Blood. 2017;129:3362–70.Google Scholar
- 41.Roberts AW, Seymour JF, Eichhorst B, et al. Pulled multi-trial analysis of venetoclax efficacy in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. ASH Annual Meeting Abstacts, Blood. 2016;128(22):3230.Google Scholar
- 44.Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980–8.CrossRefGoogle Scholar